Johnson C A, Zimmerman S W, Bayer W, Craig W A
Clin Nephrol. 1985 Mar;23(3):120-4.
The pharmacokinetics of ceftizoxime (CZM) were determined in 16 non-infected CAPD patients. Patients received either 500 mg or 1000 mg CZM by i.v. bolus. The dialysate exchange volume was 2 l. Serum CZM concentrations at 10 min were 69.7 +/- 19.7 micrograms/ml (1000 mg dose) and 39.2 +/- 8.4 micrograms/ml (500 mg dose), and declined to 33.7 +/- 13.9 micrograms/ml and 16.9 +/- 3.2 micrograms/ml respectively at 360 min. Dialysate CZM levels at 10 and 360 min were 1.8 +/- 1.3 and 19.9 +/- 6.6 micrograms/ml respectively (1000 mg dose) and 1.4 +/- 0.9 and 12.6 +/- 3.5 micrograms/ml (500 mg dose). The half-time of CZM was 14.1 +/- 4.6 h. Peritoneal clearance of CZM was low and equilibrium was not achieved in 6 h. However peritoneal CZM concentrations were adequate within 1 h for the treatment of most organisms which cause CAPD-related peritonitis.
在16名未感染的持续性非卧床腹膜透析(CAPD)患者中测定了头孢唑肟(CZM)的药代动力学。患者通过静脉推注接受500毫克或1000毫克CZM。透析液交换量为2升。10分钟时血清CZM浓度分别为69.7±19.7微克/毫升(1000毫克剂量)和39.2±8.4微克/毫升(500毫克剂量),360分钟时分别降至33.7±13.9微克/毫升和16.9±3.2微克/毫升。10分钟和360分钟时透析液中CZM水平分别为1.8±1.3和19.9±6.6微克/毫升(1000毫克剂量)以及1.4±0.9和12.6±3.5微克/毫升(500毫克剂量)。CZM的半衰期为14.1±4.6小时。CZM的腹膜清除率较低,6小时内未达到平衡。然而,1小时内腹膜CZM浓度足以治疗大多数引起CAPD相关腹膜炎的微生物。